Lab-Made Immunity: Monoclonal Antibodies Quiz

Hybridoma technology, developed by Kohler and Milstein in 1975, involves fusing an antibody-producing B cell from an immunized animal with a myeloma (cancer) cell. The resulting hybridoma cell combines the B cell's ability to produce a specific antibody with the myeloma cell's immortality, allowing indefinite production of a single, highly specific monoclonal antibody.

Monoclonal antibodies are derived from a single B cell clone and therefore all recognize the same specific epitope on an antigen. This uniformity is the defining characteristic of monoclonal antibodies. In contrast, polyclonal antibodies are produced by multiple B cell clones and target different epitopes, resulting in a heterogeneous mixture.

Myeloma cells are cancerous plasma cells that can divide indefinitely in culture. When fused with a normal antibody-producing B cell, they confer this immortality to the resulting hybridoma. Without this property, normal B cells would die after a limited number of divisions, making continuous monoclonal antibody production from a single clone impossible.

HAT medium is the selective medium used after cell fusion to isolate successfully fused hybridoma cells. Unfused myeloma cells die because aminopterin blocks their nucleotide synthesis pathway and they lack the HGPRT enzyme for the salvage route. Unfused B cells die naturally after a short time. Only hybridoma cells, which inherit HGPRT from the B cell, can survive in HAT medium.

Monoclonal antibody production through hybridoma technology involves four major steps. First, an animal is immunized to stimulate antigen-specific B cells. These are then fused with myeloma cells using polyethylene glycol. HAT medium selects only successfully fused hybridoma cells. Finally, hybridomas are screened and single-cell cloned to identify those producing the specific monoclonal antibody of interest.

One of the greatest advantages of hybridoma technology is that the resulting cell lines are immortal, inheriting this property from the myeloma fusion partner. A confirmed hybridoma clone can be maintained in culture indefinitely or stored frozen and will continue to produce the same monoclonal antibody with consistent specificity, making it a reliable and reproducible source of antibodies.

Monoclonal antibodies are identical molecules produced by a single B cell clone that all target one specific epitope. Polyclonal antibodies are a mixture produced by multiple B cell clones, each targeting a different epitope on the same antigen. Monoclonal antibodies offer higher specificity and reproducibility, which is why they are widely used in diagnostics and targeted therapies.

Mice are the most commonly used animals in hybridoma technology because their immune system is well characterized and mouse-compatible myeloma cell lines are readily available. After immunization with the target antigen, spleen cells from the mouse, which are rich in antigen-specific B cells, are harvested and fused with mouse myeloma cells to create hybridomas.

Monoclonal antibodies have transformative applications across medicine and research. In oncology, they target specific tumor antigens to inhibit cancer cell growth. In diagnostics, they are used in ELISA, immunohistochemistry, and flow cytometry for precise detection. In autoimmune disease management, monoclonal antibodies block inflammatory pathways, offering targeted treatment with fewer systemic side effects than traditional therapies.

The antigen-binding specificity of a monoclonal antibody comes entirely from the B cell used in the fusion, not the myeloma cell. The immunized B cell brings its unique B cell receptor, which determines what antigen the monoclonal antibody recognizes. The myeloma cell contributes only immortality and the cellular machinery for continuous growth and antibody production.

Polyethylene glycol (PEG) is the most commonly used agent for cell fusion in hybridoma production. PEG destabilizes cell membranes and promotes their merging, allowing the contents of the B cell and myeloma cell to combine into a single hybridoma cell. Electrical pulses (electrofusion) may also be used as an alternative method in some laboratory settings.

After HAT selection, the surviving hybridoma population still contains a mixture of different clones. Limiting dilution cloning is performed to isolate individual hybridoma cells into separate wells, ensuring each well contains a single clone. This step is essential for producing a truly monoclonal antibody, as each clone produces a single, uniform antibody with defined specificity.

Monoclonal antibodies offer several important advantages over polyclonal antibodies. Their high specificity for a single epitope reduces cross-reactivity in assays and therapies. Because they are derived from a clonal cell line, each production batch yields identical antibodies, ensuring reproducibility. This consistency and specificity make monoclonal antibodies the preferred choice for diagnostic tools and precision medicine applications.

Early monoclonal antibodies were derived entirely from mouse cells and often triggered immune reactions in human patients, a problem known as the human anti-mouse antibody (HAMA) response. Humanized monoclonal antibodies are engineered to replace most of the mouse protein sequences with human sequences, retaining only the antigen-binding regions. This significantly reduces immunogenicity and improves therapeutic safety and effectiveness.

HGPRT (hypoxanthine-guanine phosphoribosyltransferase) is an enzyme involved in the nucleotide salvage pathway. The myeloma cells used in hybridoma fusion are HGPRT-deficient, meaning they cannot survive when aminopterin blocks the de novo synthesis pathway in HAT medium. Hybridoma cells inherit HGPRT from the fused B cell, allowing them to use the salvage pathway and survive selection.